Antipsychotic Discontinuation in Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Alzheimer DiseasePsychotic DisordersAgitationAggression
Interventions
DRUG

risperidone

Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial

Trial Locations (7)

10029

Mount Sinai School of Medicine, Alzheimer's Disease Research Center, New York

10032

New York State Psychiatric Institute, Columbia University, New York

29406

Medical University of South Carolina, North Charleston

35404

Tuscaloosa VA Medical Center, Department of Psychiatry, Tuscaloosa

52242

University of Iowa College of Medicine, Iowa City

90073

WLA VA Medical Center/UCLA, Psychiatry, Los Angeles

06851

Research Center for Clinical Studies, Inc., Norwalk

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Columbia University

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT00417482 - Antipsychotic Discontinuation in Alzheimer's Disease | Biotech Hunter | Biotech Hunter